Fonte: BMC Gastroenterology. Unidades: FMRP, FM
Assuntos: DOENÇA DE CROHN, ENTEROPATIAS INFLAMATÓRIAS, INTESTINOS, TERAPIA BIOLÓGICA
ABNT
PARRA, Rogério Serafim et al. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study. BMC Gastroenterology, v. 22, 2022Tradução . . Disponível em: https://doi.org/10.1186/s12876-022-02280-3. Acesso em: 31 ago. 2024.APA
Parra, R. S., Chebli, J. M. F., Queiroz, N. S. F., Damião, A. O. M. C., Azevedo, M. F. C. de, Chebli, L. A., et al. (2022). Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study. BMC Gastroenterology, 22. doi:10.1186/s12876-022-02280-3NLM
Parra RS, Chebli JMF, Queiroz NSF, Damião AOMC, Azevedo MFC de, Chebli LA, Bertges ER, Alves Junior AJT, Ambrogini Junior O, Silva BLPS da, Lubini M, Bafutto M, Flores C, Vilela EG, Boratto SF, Gasparetti Júnior NLT, Steinwurz F, Carvalho NS, Féres O, Rocha JJR da. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study [Internet]. BMC Gastroenterology. 2022 ; 22[citado 2024 ago. 31 ] Available from: https://doi.org/10.1186/s12876-022-02280-3Vancouver
Parra RS, Chebli JMF, Queiroz NSF, Damião AOMC, Azevedo MFC de, Chebli LA, Bertges ER, Alves Junior AJT, Ambrogini Junior O, Silva BLPS da, Lubini M, Bafutto M, Flores C, Vilela EG, Boratto SF, Gasparetti Júnior NLT, Steinwurz F, Carvalho NS, Féres O, Rocha JJR da. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study [Internet]. BMC Gastroenterology. 2022 ; 22[citado 2024 ago. 31 ] Available from: https://doi.org/10.1186/s12876-022-02280-3